Evidence map›Paper›PMID 42853364›Full record

ArticleJournal of the Egyptian National Cancer Institute2026

Prediction of treatment response and survival in patients with advanced hepatocellular carcinoma receiving sorafenib: pretreatment prognostic scores.

Ammar Hatem, Mohamed Mahmoud Nabeel, Samar K Darweesh, Rania Zayed, Ashraf Omar Abdelaziz, Hend Ibrahim Shousha, Ahmed Hosni Abdelmaksoud, Eman Medhat, Tamer Mahmoud Elbaz, Mennatallah Ali Rashwan and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of the Egyptian National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ammar HatemEndemic Medicine Department, Faculty of medicine, Cairo University, Giza, Egypt.
Mohamed Mahmoud NabeelEndemic Medicine Department, Faculty of medicine, Cairo University, Giza, Egypt.ORCID https://orcid.org/0000-0001-6002-9858
Samar K DarweeshEndemic Medicine Department, Faculty of medicine, Cairo University, Giza, Egypt.
Rania ZayedClinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Giza, Egypt.
Ashraf Omar AbdelazizEndemic Medicine Department, Faculty of medicine, Cairo University, Giza, Egypt.
Hend Ibrahim ShoushaEndemic Medicine Department, Faculty of medicine, Cairo University, Giza, Egypt.
Ahmed Hosni AbdelmaksoudDiagnostic and Interventional Radiology Department, Faculty of Medicine, Cairo University, Giza, Egypt.
Eman MedhatEndemic Medicine Department, Faculty of medicine, Cairo University, Giza, Egypt.
Tamer Mahmoud ElbazEndemic Medicine Department, Faculty of medicine, Cairo University, Giza, Egypt.
Mennatallah Ali RashwanEndemic Medicine Department, Faculty of medicine, Cairo University, Giza, Egypt. menna.hussain38808@postgrad.kasralainy.edu.eg.
Ahmed RamadanEndemic Medicine Department, Faculty of medicine, Cairo University, Giza, Egypt.
Rania LithyEndemic Medicine Department, Faculty of medicine, Cairo University, Giza, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSorafenib is currently among the recommended first-line medications for patients with advanced hepatocellular carcinoma (HCC); however, response to sorafenib remains unpredictable despite efforts to define prognosis. This study aims to predict treatment response and survival in patients with sorafenib-treated HCC using neutrophil-to-lymphocyte ratio (NLR), albumin-bilirubin (ALBI) grade, CRAFITY score, and Glasgow prognostic score (GPS).

methodsThis prospective study recruited 75 Egyptian patients with Sorafenib-treated HCC. Pretreatment laboratory parameters and imaging studies were obtained. The neutrophil-to-lymphocyte ratio, ALBI grade, CRAFITY score, and GPS were calculated for each patient. All the patients were followed for treatment response, overall survival, and sorafenib tolerance.

resultsMost of the participants were males, with a median age of 62 years. HCV was the most common underlying cause. Most of the patients had a low pretreatment NLR (77.33%), grade 2 ALBI (65.33%), 41.89% had a high CRAFITY score, and 48.6% had GPS 1. Patients were divided into two groups: group 1: sorafenib-naïve (n = 44) and group 2: patients with previous interventional therapy (n = 31). Pretreatment AST, ALT, mild ascites, portal invasion, and BCLC stage C were significantly higher among sorafenib-naïve patients. Median OS and time to progression for the entire cohort were 4 months and 9 months, respectively. No significant differences were observed in terms of OS between various NLR, ALBI grades, CRAFITY scores, and GPS. Multivariate analysis showed a high risk of mortality among sorafenib-intolerant patients (p = 0.01, HR: 2.33, 95% CI: 1.23-4.42).

conclusionOverall survival and time to progression are not affected by different pretreatment values of NLR, ALBI grade, CRAFITY score, and Glasgow prognostic score in sorafenib-treated HCC.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularLiver NeoplasmsNiacinamidePhenylurea CompoundsAdultAgedFemaleHumansLymphocytesMaleMiddle AgedNeoplasm StagingNeutrophilsPrognosisProspective StudiesAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenibHepatocellular carcinomaPredictorsSorafenibSurvival

Identifiers

PMID42853364

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.